Bioray Biotech CoROCO:7561 -1.84%83 EBITDA Margin % is 26.61% as of Dec. 2025, which is 109% above its 10-year median of 12.74. GuruFocus rates ROCO:7561 with a GF Score™ of 83/100 and a GF Value™ of NT$29.46 (Significantly Undervalued). Among 952 Drug Manufacturers companies, Bioray Biotech Co ranks better than 84.98% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bioray Biotech Co's EBITDA for the
six
months ended in Dec. 2025 was NT$28.9 Mil. Bioray Biotech Co's Revenue for the
six
months ended in Dec. 2025 was NT$108.6 Mil. Therefore, Bioray Biotech Co's EBITDA margin for the quarter that ended in Dec. 2025 was 26.61%.
Bioray Biotech Co (ROCO:7561) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bioray Biotech Co EBITDA Margin % Related Terms
Bioray Biotech Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bioray Biotech Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7561 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioray Biotech Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bioray Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioray Biotech Co (ROCO:7561) has a EBITDA Margin % of 26.61% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioray Biotech Co and its competitors. This is 109% above median its historical median of 12.74. Over the past decade, Bioray Biotech Co's EBITDA Margin % has ranged from 6.33 to 29.40. According to the industry distribution chart, Bioray Biotech Co ranks #143 out of 952 companies in the Drug Manufacturers industry, placing it in the top 15%.
Is Bioray Biotech Co's EBITDA Margin % too high?
Bioray Biotech Co's current EBITDA Margin % of 26.61% is 109% above median its 10-year median of 12.74. Over the past 10 years, this metric has ranged from a low of 6.33 to a high of 29.40. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Bioray Biotech Co's value of 26.61% is 113.4% above this industry median. Based on the distribution chart, Bioray Biotech Co ranks #143 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bioray Biotech Co has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bioray Biotech Co ranks #143 out of 952 companies for EBITDA Margin %. This places Bioray Biotech Co in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Bioray Biotech Co's value of 26.61% is 113.4% above this benchmark. Historically, Bioray Biotech Co's own EBITDA Margin % has ranged from 6.33 to 29.40 over the past decade. While the company's 10-year median is 12.74 vs. the industry median of 12.47, Bioray Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioray Biotech Co's current EBITDA Margin % of 26.61% is 113.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioray Biotech Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioray Biotech Co's current EBITDA Margin % is 26.61%, which is 109% above median its own 10-year median of 12.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$29.46, compared to a current price of NT$18.65 — trading 36.7% below its estimated fair value. The current EBITDA Margin % is 26.61%, which is 109% above median its 10-year median of 12.74 and 113.4% above the Drug Manufacturers industry median of 12.47. Bioray Biotech Co's overall GF Score™ is 83/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current EBITDA Margin % is 26.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?
Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued.
The current stock price of NT$18.65 is trading 36.7% below its estimated GF Value™ of NT$29.46.
GuruFocus considers Bioray Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:7561:
EBITDA Margin %: 26.61% (109% above median its 10-year median of 12.74)
GF Value™: NT$29.46 vs. price of NT$18.65 (36.7% below fair value)
Industry Position: 113.4% above the Drug Manufacturers median (#143 of 952)
No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
83GF Score
Get the complete analysis for ROCO:7561
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7561 has been successfully added to your 
